Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 1/20 | 0.34 |
| ▸ | FFAR4 | Q5NUL3 | 6/20 | 0.33 |
| ▸ | FASN | P49327 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 5/20 | 0.32 |
| ▸ | TP53 | P04637 | 4/20 | 0.32 |
| ▸ | MME | P08473 | 3/20 | 0.32 |
| ▸ | DPP4 | P27487 | 1/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24381008 | 1.00 | PAK1 (0.34) | PAK1FFAR4FASNMDM2TP53 | |
| SCHEMBL24380864 | 0.94 | PAK1 (0.34) | PAK1FFAR4FASNMDM2TP53 | |
| SCHEMBL24380867 | 0.94 | PAK1 (0.34) | PAK1FFAR4FASNMDM2TP53 | |
| SCHEMBL24380919 | 0.92 | PAK1 (0.34) | PAK1FFAR4FASNMDM2TP53 | |
| SCHEMBL18595124 | 0.92 | PAK1 (0.34) | PAK1FFAR4FASNMDM2TP53 | |
| SCHEMBL16983677 | 0.92 | PAK1 (0.36) | PAK1FFAR4FASNMDM2TP53 | |
| SCHEMBL24380853 | 0.92 | PAK1 (0.36) | PAK1FFAR4FASNMDM2TP53 | |
| SCHEMBL24381004 | 0.91 | FFAR4 (0.34) | PAK1FFAR4FASNMDM2TP53 | |
| SCHEMBL24381007 | 0.91 | FFAR4 (0.34) | PAK1FFAR4FASNMDM2TP53 | |
| SCHEMBL19086027 | 0.89 | PAK1 (0.33) | PAK1FFAR4FASNMME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | PAK1 2053/4885FFAR4 3166/4885FASN 3583/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.